Please ensure Javascript is enabled for purposes of website accessibility

These Drugs Are Actually Moving The Needle For Johnson & Johnson

By Motley Fool Staff – Feb 1, 2016 at 1:03PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Sales for its hepatitis C drug are falling off a cliff, but revenue from these fast-growing therapies more than make up for it.

Johnson & Johnson's (JNJ -0.71%) reported less-than-stellar results on its recent earnings call largely because of currency issues and poor performance of former-knockout hepatitis C drug Olysio.

In this video segment, Motley Fool healthcare contributor Todd Campbell shares with analyst Kristine Harjes which Johnson & Johnson drugs he thinks investors ought to be paying attention to in 2016. And despite it hauling in hundreds of millions of dollars in sales last year, the list doesn't include Olysio.

A full transcript follows the video.


This podcast was recorded on Jan. 27, 2016.

Todd Campbell: The reason that people may want to not think too much about Olysio, and think instead about the other drugs that Johnson & Johnson has going on, in the success they're having with these other drugs, one of my favorites of all of those drugs has got to be Invokana. It's a type 2 diabetes drug, it's an SGLT2 drug, which simply means that it works very differently by helping to prevent how much glucose gets reabsorbed, and therefore, it allows more to get excreted by the patient. That drug has taken off like gangbusters.

Sales more than doubled in the past year to $1.3 billion. It's also got some other really intriguing drugs are doing well: Imbruvica, which is an oncology drug that they're partnering up with AbbVie on, that's now over $1 billion a year drug globally. Their share of that rose from $200 million to over $600 million last year. It's also got a drug for psoriasis called Stelara, which is dosed much less frequently than their top-selling Remicadeand other anti-TNF drugs that are used in autoimmune disease drugs. That drug saw its sales jump significantly to $2.4-$2.5 billion last year. So, there's a lot of drugs that are doing very well for the company that investors may want to focus on instead of Olysio, which is basically going to continue to see its sales decline and decline, as other hepatitis C drugs come to market.

Kristine Harjes: One thing I'll add on: Remicade has been the pivotal focus of the discussion on biosimilars, and whether or not that threat will become apparent to Johnson & Johnson. As a reminder, biosimilars are essentially generic versions of biologic drugs. So, they're a lot harder to make, they're not going to sell for as much of a discount, and they're pretty new, so we're still figuring out what exactly it means for some of these gigantic healthcare companies to face competition from newly introduced biosimilars.

Kristine Harjes owns shares of Johnson & Johnson. Todd Campbell has no position in any stocks mentioned. The Motley Fool recommends Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Johnson & Johnson Stock Quote
Johnson & Johnson
$163.36 (-0.71%) $-1.17

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/02/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.